A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

Inclusion Criteria:

1. Agree to comply with the trial treatment plan and visit plan, voluntarily agree tosign the informed consent form;

2. 18-75 years old (including boundary value), no gender limit in the I/IIa trialphase；18-80 years old (including boundary value), no gender limit in the IIb trialphase；

3. Subject has adequate organ and bone marrow function，Conforming to laboratory testresults:

4. The expected survival time is at least 12 weeks

5. ECOG score is 0-1

6. Males with fertility and females of childbearing age are willing to take effectivecontraceptive measures From the signing of the informed consent form to within 6months after the last administration of the trial drug (including abstinence,intrauterine device, various hormonal contraception, correct use of contraceptionSets，etc）; Women of childbearing age include pre-menopausal women and women within 2years after menopause. Women of childbearing age must have a negative pregnancy testwithin 7 days before the first trial drug is administered.

Exclusion Criteria:

1. Receiving other unmarketed clinical research drugs or treatments within 4 weeksbefore using the research drug for the first time;

2. Brain parenchymal metastases or meningeal metastases with clinical symptoms, whichare not suitable for inclusion in the group by the investigator's judgment;

3. medical history of immunodeficiency including positive HIV antibody test;

4. Women who are pregnant or breastfeeding;

5. The investigator believes that the subject has other conditions that may affectcompliance or are not suitable for participating in the study